NEW YORK , March 5, 2024 /PRNewswire/ -- Lindus Health, an 'anti-CRO' running radically faster, more reliable clinical trials for life science pioneers, has launched an all-in-one package of contract research organization (CRO) services, site services and clinical trial technology to support research within the metabolic space..

纽约，2024年3月5日/PRNewswire/--Lindus Health是一家为生命科学先驱进行速度更快、更可靠的临床试验的“反CRO”，它推出了合同研究组织（CRO）服务、现场服务和临床试验技术的一体化包，以支持代谢空间内的研究。。

Lindus Health has an extensive track record in metabolic diseases, executing 18 end-to-end studies, with over 1,600 patients enrolled in the US and Europe in indications such as obesity, diabetes and more. Lindus has taken learnings from this experience to build a bespoke 'All-in-One Metabolic CRO' offering that combines the expertise of a seasoned full service CRO and internal site/PI expertise with a distinctive technology driven approach on its proprietary Citrus™ platform.

林德斯健康（Lindus Health）在代谢疾病方面有着广泛的记录，进行了18项端到端研究，在美国和欧洲有1600多名患者因肥胖、糖尿病等适应症入选。林德斯从这一经验中吸取教训，构建了一个定制的“一体式代谢CRO”产品，该产品将经验丰富的全服务CRO的专业知识和内部站点/PI专业知识与专有柑橘™平台上独特的技术驱动方法相结合。

This unique marriage of technology and services sets metabolic sponsors up to run faster, more patient-centric clinical trials..

这种技术和服务的独特结合使代谢赞助商能够更快，更以患者为中心的临床试验。。

'With the prevalence of metabolic disease growing on a global scale, and the massive uptick in research with the advent of GLP-1s, we want to use our unique expertise and capabilities to accelerate approvals of these essential therapies,' says Emma Ogburn, VP of Clinical Operations at Lindus Health.

林德斯健康公司（Lindus Health）临床运营副总裁艾玛·奥格本（Emma Ogburn）说：“随着代谢性疾病在全球范围内的流行，以及GLP-1的出现使研究大幅上升，我们希望利用我们独特的专业知识和能力来加速这些基本疗法的批准。”。

'Our All-in-One Metabolic CRO offering is designed to streamline study activities at every stage of research. We're thrilled to be applying our extensive metabolic expertise to offer an all-in-one approach including study execution, site management, and technology services to sponsors in this area.'.

“我们的一体式代谢CRO产品旨在简化研究每个阶段的研究活动。我们很高兴能够应用我们广泛的代谢专业知识，为该领域的赞助商提供包括研究执行，现场管理和技术服务在内的一体化方法。”。

Lindus Health has built a strong reputation for accelerating and bringing metabolic interventions to market garnering the support from a world-class advisory board, including newly appointed advisor Robert Langer, renowned MIT professor and co-founder of Moderna as well as metabolic industry leaders such as Carel Le Roux, Professor of Experimental Pathology at the University of Dublin, and Dimitar Tonev, hepatologist with extensive experience in NASH research..

林德斯健康（Lindus Health）在加速代谢干预并将其推向市场方面树立了良好的声誉，获得了世界级咨询委员会的支持，其中包括新任命的顾问罗伯特·兰格（Robert Langer），麻省理工学院著名教授兼Moderna联合创始人，以及代谢行业的领导者，如都柏林大学实验病理学教授Carel Le Roux，以及在NASH研究方面拥有丰富经验的肝病学家Dimitar Tonev。。

'We've had the privilege of collaborating with Lindus Health, and their team's attentiveness and dedication have been beyond our expectations, said CEO Thomas Gurry, Co-Founder and CEO of Myota, a health tech start-up that aims to improve well-being and prevent chronic diseases. 'Their passion is evident in every aspect of their work, from meticulous study planning to execution.'.

Myota是一家旨在改善健康状况和预防慢性病的健康技术初创公司，其联合创始人兼首席执行官托马斯·古里（ThomasGurry）表示，我们有幸与林德斯健康合作，他们团队的专注和奉献精神超出了我们的预期他们的热情体现在工作的各个方面，从细致的学习计划到执行。”。

Lindus Health includes the following services and features within their 'All-in-One Metabolic CRO' offering:

林德斯健康在其“一体式代谢CRO”产品中包括以下服务和功能：

End-to-end trial management and execution services: Lindus' offer covers the entire study delivery value chain, from designing effective study protocols and recruitment strategies specific to these patient populations, all the way through data collection, management, and delivery.

端到端试验管理和执行服务：林德斯的服务涵盖了整个研究交付价值链，从设计针对这些患者群体的有效研究方案和招募策略，一直到数据收集，管理和交付。

Expertise in regulatory affairs and the metabolic market segment: With experience in preparing ethics submissions in numerous countries, Lindus Health's team stays current with the ever-changing regulatory landscapes across the globe especially in metabolic health.

监管事务和代谢市场细分领域的专业知识：凭借在许多国家编写道德提交文件的经验，林德斯健康的团队能够及时了解全球不断变化的监管环境，尤其是代谢健康领域。

Patient recruitment powered by technology: Lindus helps metabolic sponsors achieve enrollment goals on-time by leveraging a variety of different recruitment strategies. With an extensive network of over 30 million electronic health records (EHRs) and a dedicated digital marketing team for multi-channel recruitment initiatives, the company has demonstrated success in targeting various patient populations to participate in metabolic studies..

技术支持的患者招募：林德斯通过利用各种不同的招募策略，帮助代谢赞助商按时实现注册目标。该公司拥有超过3000万份电子健康记录（EHR）的广泛网络和一支专门的数字营销团队，用于多渠道招聘计划，在针对不同患者群体参与代谢研究方面取得了成功。。

End-to End eClinical 'Citrus™' Platform: Citrus™, Lindus Health's proprietary home-grown Clinical Trial Management S(CTMS) and Electronic Data Capture (EDC) software, unites all the essential technologies to run clinical trials under one roof, mitigating the risks associated with fragmentation of data across multiple software products..

端到端eClinical“Citrus™”平台：Citrus™，Lindus Health专有的自制临床试验管理（CTMS）和电子数据采集（EDC）软件，将所有基本技术结合在一起，在一个屋顶下运行临床试验，减轻了与多个软件产品数据碎片化相关的风险。。

Site management services: Lindus Health's in-house site operations team has supported single and multi-site studies as well as traditional to fully virtual and hybrid clinical trial models within metabolic research. Lindus carries a site team with extensive resumes in the metabolic study execution that cover roles across PIs, CRCs, and more..

现场管理服务：林德斯健康公司的内部现场运营团队支持代谢研究中的单点和多点研究以及传统到完全虚拟和混合临床试验模型。Lindus拥有一个现场团队，在代谢研究执行中有大量的简历，涵盖了PI，CRC等领域的角色。。

Therapeutics for metabolic medical conditions range from traditional pharmaceuticals to medical devices to digital therapeutic technologies. One compound of particular interest is GLP-1 receptor agonists, which are currently used to treat diabetes and obesity, but quickly expanding with research to many other indications..

代谢性疾病的治疗方法从传统药物到医疗设备再到数字治疗技术。一种特别令人感兴趣的化合物是GLP-1受体激动剂，目前用于治疗糖尿病和肥胖症，但随着对许多其他适应症的研究迅速扩大。。

Lindus Health's all-encompassing Metabolic CRO offering empowers metabolic disease sponsors to run more timely and successful clinical trials while enhancing patient experience.

林德斯健康（Lindus Health）全面的代谢CRO服务使代谢疾病赞助商能够在提高患者体验的同时进行更及时和成功的临床试验。

To learn more about Lindus Health's solution for the metabolic market segment, click here.

要了解林德斯健康针对代谢市场细分的解决方案的更多信息，请单击此处。

About Lindus Health

关于林德斯健康

Lindus Health is an anti-CRO running radically faster and more reliable trials for life science pioneers – bringing ground-breaking treatments to patients more quickly. Lindus Health does this thanks to a commercial model that aligns incentives (fixed-priced quotes per study, with milestone-based payments), marrying a world-class clinical operations team with its unique software platform, and access to 30 million Electronic Health Records.

Lindus Health是一家反CRO的公司，为生命科学先驱进行了速度更快、更可靠的试验，为患者带来了突破性的治疗。林德斯健康（Lindus Health）之所以能够做到这一点，得益于一种商业模式，该模式将激励措施（每项研究的固定价格报价，以及基于里程碑的付款）与世界一流的临床运营团队及其独特的软件平台结合在一起，并可以访问3000万份电子健康记录。

Clinical trials are the biggest bottleneck to advances in healthcare and by removing this constraint they aim to improve health for everyone. They handle the end-to-end execution of clinical studies, including design, patient recruitment, clinical data capture, monitoring and project management..

临床试验是医疗保健进步的最大瓶颈，通过消除这一限制，他们旨在改善每个人的健康。他们负责临床研究的端到端执行，包括设计、患者招募、临床数据采集、监测和项目管理。。

‍Lindus Health has to date delivered more than 90 trials across the US, UK and Europe to tackle a range of conditions including diabetes, asthma, acne, social anxiety, major depressive disorder, hypertension, chronic fatigue syndrome and insomnia.

‍迄今为止，Lindus Health已在美国、英国和欧洲进行了90多项试验，以应对一系列疾病，包括糖尿病、哮喘、痤疮、社交焦虑症、重度抑郁症、高血压、慢性疲劳综合征和失眠。

The company was named after James Lind, who pioneered the first clinical trial and treatment for scurvy, and co-founded by Michael Young, a former Special Adviser to the UK Prime Minister on Life Sciences, and Meri Beckwith, a former life sciences investor.

该公司以詹姆斯·林德（JamesLind）的名字命名，詹姆斯·林德是坏血病第一次临床试验和治疗的先驱，由英国前首相生命科学特别顾问迈克尔·杨（MichaelYoung）和前生命科学投资者梅里·贝克维思（MeriBeckwith）共同创立。

The company has raised over $24M from investors including Peter Thiel, CREANDUM, Firstminute Capital, Presight Capital, Seedcamp, Hambro Perks, Amino Collective and Calm/Storm.

该公司已从包括Peter Thiel、CREANDUM、Firstminute Capital、Presight Capital、Seedcamp、Hambro Perks、Amino Collective和Calm/Storm在内的投资者那里筹集了2400多万美元。

Media Contact:Jodi PerkinsAmendola for Lindus Healthjperkins@acmarketingpr.com

媒体联系人：Jodi PerkinsAmendola代表LindusHealthjperkins@acmarketingpr.com

SOURCE Lindus Health

来源Lindus Health